World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(RESEARCH ARTICLE)

Check for updates

Structural analysis of isonicotinic hydrazide Basic units

Neha Nathu Dalavi *, Rahul Prakash Lokhande, Harshala Tanaji Gholap, Tejaswini Harishchandra Gholap and Vaijyanti Sadanand Gholap

Samarth Institute of Pharmacy, Belhe, Maharashtra, India-412210.

World Journal of Biology Pharmacy and Health Sciences, 2024, 18(03), 174–179

Publication history: Received on 15 April 2024; revised on 27 May 2024; accepted on 30 May 2024

Article DOI: https://doi.org/10.30574/wjbphs.2024.18.3.0309

Abstract

Isoniazid, too known as isoniazid (INH), is an anti-microbial utilized to treat tuberculosis. Its part is to anticipate the blend of mycolic corrosive, an imperative component of the bacterial divider. INH is considered a first-line treatment for tuberculosis and is regularly utilized in combination with other anti-microbials to avoid the rise of medicate resistance. Its substance may center on its chemical structure, mode of activity, clinical utilize and side impacts. In 1912 the primary amalgamation was portrayed. A. Kachugin created an anti-microbial called Tubazid in 1949. The revelation of isoniazid made the treatment of the malady conceivable. Hydrazones are compounds with azomethine-NHN=CH bunches that have been broadly examined due to their ease of arrangement and numerous chemical benefits. INH is considered the first-line treatment for tuberculosis and is regularly utilized in combination with other anti-microbials to treat the infection. It avoids the arrangement of anti-inflammatory drugs. Its unique seem center on its chemical structure, mode of activity, restorative utilize, and potential side impacts.

Keywords: Inhibitory concentration; Azomethine; Cytotoxicity; Hydrozone

1. Introduction



Figure 1 Basic structure of isonicotinic hydrazide

Isoniazid, commonly known as isoniazid (INH), is an important drug in the treatment of tuberculosis (TB) and is widely recognized for its effectiveness against this infectious disease. Initially synthesized in the early 1950s, INH revolutionized TB therapy by targeting the bacteria responsible for the illness. Its introduction into medical practice significantly reduced mortality rates associated with TB and became a cornerstone in the management of this global health concern. This introduction could explore its historical context, discovery, and initial applications in the treatment of tuberculosis. Isoniazid hydrazide (isoniazid or INH) 3 is a widely used antibiotic that is required to interact with Mycobacterium tuberculosis catalase KatG (MtKatG).(1)

* Corresponding author:

2. History

First synthesis was described in 1912.(1)

Isoniazid and Other Drugs Iproniazid is one of the first known antidepressant drugs..(2)

Structural activity relationship :-



Figure 2 Structural requirement for the antimycobacterial and antimicrobial activities of synthesize Isoniazid derivative's

The association between the following structural activity and the antibacterial activity results can be inferred:

The substances exhibit strong antifungal Possibility in contrast to antimicrobial activity, which Demonstrates that several structural requirements exist. Are necessary for the antifungal and antibacterial properties. Additionally, it is evident from the outcomes of antibacterial and Antifungal properties, with a rise in activity corresponding to the Heavier substituent being added to the phenyl nucleus Among the artificial substances that are readily Evidenced from compound 1's increased activity in Contrast with compounds 2 and 6 in contrast with Chemical 5 in that order.(1)

Antimicrobial activity studies showed that teath The existence of donating electrons. OCH improved the synthetic derivatives' antibacterial efficacy. Compound 2's antimicrobial activity results show that it was active. Compound 3's addition of OCH group increased compound 2's activity, and compound 4's additional addition of OCH group made the molecule's structure extremely active against the strains that were tested. There are results to support this.(2, 3)

Compared to the Gram-positive bacteria B. subtilis and & aureus, the produced compounds showed greater activity against the Gram-negative bacterium E col. This result is consistent with the findings of Sbardella at al.

The substitution of NH protein with acyl group Compounds 10–14 exhibit increased activity when the NH proton is substituted with an acyl group. This could be because of the rise in The molecules' lipophilicity, which could enable them To pass through the microbial membrane with ease. Such The outcomes correspond with the findings of The Imramovsky group (2007). These outcomes are not comparable . Based on the antimycobacterial activity findings, where the Activity is reduced as a result of N1-benzoylation

The use of an acyl group in place of NH protein When an acyl group is added in place of the NH proton, compounds 10–14 become more active. This may be a result of the increase in The lipophilicity of the molecules, which might allow them to effortlessly cross the microbial membrane. Like that The results align with the conclusions of Imramovsky collective (2007). These results are not interchangeable. According to the results of the antimycobacterial activity, where the Reduced activity is the result of N1-benzoylation.

3. Mechanism of action



Figure 3 Activation of isoniazid and formation of isonicotinic acyl-NADH

-An anti-mycobacterial cell divider inhibitor is isoniazid. The catalase-peroxidase KatG in Mycobacterium tuberculosis is required for isoniazid actuation. (37) KatG shapes an isonicotinoyl radical, which at that point suddenly combines with NADH to create a nicotinoyl-NAD adduct. This complex ties firmly to the enoyl-acyl carrier protein reductase InhA, hindering the capacity of greasy corrosive synthase and the local enoyl-AcpM substrate. Mycolic corrosive is an vital portion of the mycobacterial divider and this prepare restrains their union. Nitric oxide is one of the free radicals delivered when isoniazid is actuated by KatG.[38]. This free radical has too been appeared to play an critical part within the activity of another anti-inflammatory sedate, pretomanid. (6)



Figure 4 Baeyer-Villiger monooxygenases EthA and to a lesser extent, MymA, are required for bioactivation of ethionamide (ETH). Development of EthR inhibitors is proposed as a therapeutic strategy to boost the expression of ethA and thus the bioactivation of ETH inside the mycobacteria

4. Pharmacokinetic

4.1. Administration and Distribution

- Administration:-Isoniazid is commonly administered orally but can also be given intramuscularly.- fluid.
- Distribution:- It permeates all body tissues and fluids, including inflamed meninges, reaching therapeutic levels in the cerebrospinal fluid (CSF).

4.2. Metabolism and Excretion

- Metabolism:-It is metabolized to an inactive form mainly by acetylation in the liver.
- Half-life:-Ranges from 1 to 4 hours, dependent on the patient's acetylation rate. Its efficacy remains consistent when dosed once daily.
- Excretion:-About 75% and its metabolites are excreted in urine, with the remaining portion excreted in faces, saliva, and sputum.

4.3. Cytochrome P450 Interactions

- Affected Enzymes:- Isoniazid interacts with various cytochrome P450 isoenzyme, including CYP2C19, CYP3A4, CYP2A6, CYP2C9, CYP2D6, and CYP2E1.
- Inhibition and Interaction:-It notably inhibits CYP2C19 and CYP3A4, weakly affecting CYP2A6, CYP2C9, and CYP2D6. Its impact on CYP1A2 is uncertain, likely showing minimal inhibition. Additionally, isoniazid both inhibits and induces the hepatic isoenzyme CYP2E1. This dual effect involves competitive blocking of the active site, reducing substrate metabolism, and temporarily increasing enzymatic activity after dissociation.

4.4. Oral Route

- Absorption:- Rapid absorption from the gastrointestinal (GI) tract after oral intake, reaching peak serum levels within 1 to 2 hours. Food intake slows both the rate and extent of absorption.

In Isoniazid (INH), two essential moieties are present

Table 1 Two essential moiety of isoniazid

Isotonic acid moiety	hydrazide group
This part is responsible for the is nicotinic acid structure within the compound.	Comprising two nitrogen atoms bonded together, this group gives INH its hydrazide structure, which is crucial for its pharmacological activity against tuberculosis.
forms the backbone of the compound, providing the core structure derived from isonicotinic acid. This moiety contributes to the compound's overall chemical properties and reactivity	This functional group consist of two nitrogen atom linked by a double bond. Its essential part of INHs structure conferring specific The pharmacological activity involves the inhibition of mycolic acid synthesis within the cell wall of Mycobacterim Tuberculosis

Both moieties collectively contribute to the unique pharmacological action of INH against tuberculosis, with the isonicotinic acid moiety providing the base structure and the hydrazide group imparting specific antimicrobial activity.

4.5. Defects cause by Isonicotinic Hydrazide

Common side impacts of Isoniazid (INH) can incorporate fringe neuropathy (shivering, deadness in hands and feet), hepatotoxicity (liver harm), gastrointestinal disturbed (queasiness, heaving), and skin rashes furthermore a few people may encounter drug-induced lupus-like syndrome or touchiness responses. Standard checking and provoke detailing of any side impacts to a healthcare proficient are fundamental amid INH treatment.

Isoniazid (INH) can have different side impacts, in spite of the fact that not everybody encounters them. Common ones incorporate queasiness, heaving, and neurological issues like fringe neuropathy. A few people may too experience liver issues, such as hepatitis. Uncommon but genuine side impacts can include extreme unfavorably susceptible responses or indeed psychosis. Checking and appropriate therapeutic supervision amid INH treatment offer assistance oversee these potential side impacts effectively.

Touchiness responses such as sedate fever, hasty, lymphadenopathy, vasculitis, and urticaria are uncommon but detailed with Isoniazid (INH). These responses more often than not resolve after ceasing the medicate. Gastrointestinal antagonistic impacts like sickness, spewing, and epigastric distress are common. Moreover, many cases of pancreatitis have been recorded.

5. Conclusion

Isoniazid (INH) is a crucial component of tuberculosis therapy, renowned for its effectiveness in inhibiting mycolic acid synthesis in Mycobacterium tuberculosis, thus demonstrating its efficacy in combating this infectious illness.

While INH demonstrates remarkable effectiveness, its use can be accompanied by notable side effects such as peripheral neuropathy and hepatotoxicity. Nonetheless, the balance between its benefits in treating tuberculosis and the management of potential side effects underscores its importance in current therapeutic protocols. Continued research and vigilance in monitoring its administration remain crucial for maximizing its benefits while minimizing adverse effects in tuberculosis management.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Wengenack N., Rusnak F. (2001) Biochemistry 40, 8990–8996

[2] Amos R. I., Gourlay B. S., Schiesser C. H., Smith J. A., Yates B. F. (2008) Chem. Commun. 1695–1697

[3] Metcalfe C., Macdonald I. K., Murphy E. J., Brown K. A., Raven E. L., Moody P. C. E. (2008) J. Biol. Chem. 283, 6193–6200

[4] Singh A. K., Kumar R. P., Pandey N., Singh N., Sinha M., Bhushan A., Kaur P., Sharma S., Singh T. P. (2010) J. Biol. Chem. 285, 1569–1576

[5] Carpena X., Wiseman B., Deemagarn T., Herguedas B., Ivancich A., Singh R., Loewen P. C., Fita I. (2006) Biochemistry 45, 5171–5179

[6] Carpena X., Wiseman B., Deemagarn T., Singh R., Switala J., Ivancich A., Fita I., Loewen P. C. (2005) EMBO Rep. 6, 1156–1162

[7] Dunford H. B. (1999) Heme Peroxidases, pp 97–101, Wiley-VCH, New York

[8] Farrington J. A., Land E. J., Swallow A. J. (1980) Biochim. Biophys. Acta 590, 273–276

[9] Todorović S., Juranić N., Macura S., Rusnak F. (1999) J. Am. Chem. Soc. 121, 10962–10966

[10] Deemagarn T., Wiseman B., Carpena X., Ivancich A., Fita I., Loewen P. C. (2007) Proteins 66, 219–228

[11] Shoeb H. A., Bowman B. U., Jr., Ottolenghi A. C., Merola A. J. (1985) Antimicrob. Agents Chemother. 27, 408–412

[12] Deemagarn T., Carpena X., Singh R., Wiseman B., Fita I., Loewen P. C. (2005) J. Mol. Biol. 345, 21–28

[13] Yamada Y., Saijo S., Sato T., Igarashi N., Usui H., Fujiwara T., Tanaka N. (2001) Acta Crystallog. D57, 1157–1158

[14] Yamada Y., Fujiwara T., Sato T., Igarashi N., Tanaka N. (2002) Nature Struct. Biol. 9, 691–695

[15] Wada K., Tada T., Nakamura Y., Kinoshita T., Tamoi M., Shigeoka S., Nishimura K. (2002) Acta Crystallogr. D Biol. Crystallogr. 58, 157–159

[16] Carpena X., Switala J., Loprasert S., Mongkolsuk S., Fita I., Loewen P. C. (2002) Acta Crystallogr. D Biol. Crystallogr. 58, 2184–2186

[17] Carpena X., Loprasert S., Mongkolsuk S., Switala J., Loewen P. C., Fita I. (2003) J. Mol. Biol. 327, 475–489

[18] Bertrand T., Eady N. A., Jones J. N., Jesmin Nagy J. M., Jamart-Grégoire B., Raven E. L., Brown K. A. (2004) J. Biol. Chem. 279, 38991–38999

[19] Colin J., Wiseman B., Switala J., Loewen P. C., Ivancich A. (2009) J. Am. Chem. Soc. 131, 8557–8563

[20] Kunkel T. A., Roberts J. D., Zakour R. A. (1987) Methods Enzymol. 154, 367–382

[21] Wengenack N. L., Hoard H. M., Rusnak F. (1999) J. Am. Chem. Soc. 121, 9748–9749

[22] Lei B., Wei C. J., Tu S. C. (2000) J. Biol. Chem. 275, 2520–2526

[23] Vilchèze C., Morbidoni H. R., Weisbrod T. R., Iwamoto H., Kuo M., Sacchettini J. C., Jacobs W. R., Jr. (2000) J. Bacteriol. 182, 4059–4067

[24] Zabinski R. F., Blanchard J. S. (1997) J. Am. Chem. Soc. 119, 2331–2332

[25] Singh R., Wiseman B., Deemagarn T., Donald L. J., Duckworth H. W., Carpena X., Fita I., Loewen P. C. (2004) J. Biol. Chem. 279, 43098–43106

[26] Singh R., Wiseman B., Deemagarn T., Jha V., Switala J., Loewen P. C. (2008) Arch. Biochem. Biophys. 471, 207–214

[27] Magliozzo R. S., Marcinkeviciene J. A. (1996) J. Am. Chem. Soc. 118, 11303–11304

[28] Wang J. Y., Burger R. M., Drlica K. (1998) Antimicrob. Agents Chemother. 42, 709–711

[29] Shoeb H. A., Bowman B. U., Jr., Ottolenghi A. C., Merola A. J. (1985) Antimicrob. Agents Chemother. 27, 404–407

[30] Shoeb H. A., Bowman B. U., Jr., Ottolenghi A. C., Merola A. J. (1985) Antimicrob. Agents Chemother. 27, 399–403

[31] Zhang Y., Heym B., Allen B., Young D., Cole S. (1992) Nature 358, 591–593

[32] Rozwarski D. A., Grant G. A., Bartom D. H., Jacobs W. R., Jr., Sacchettini J. C. (1998) Science 279, 98–102

[33] Chouchane S., Lippai I., Magliozzo R. S. (2000) Biochemistry 39, 9975–9983

[34] Ghiladi R. A., Cabelli D. E., Ortiz de Montellano P. R. (2004) J. Am. Chem. Soc. 126, 4772–4773

[35] Ghiladi R. A., Medzihradszky K. F., Rusnak F. M., Ortiz de Montellano P. R. (2005) J. Am. Chem. Soc. 127, 13428–13442

[36] Cade C. E., Dlouhy A. C., Medzihradszky K. F., Salas-Castillo S. P., Ghiladi R. A. (2010) Prot. Sci. 19, 458–474

[37] Zhao X., Yu H., Yu S., Wang F., Sacchettini J. C., Magliozzo R. S. (2006) Biochemistry 45, 4131–4140

[38] Singh R., Switala J., Loewen P. C., Ivancich A. (2007) J. Am. Chem. Soc. 129, 15954–15963

[39] Wengenack N. L., Uhl J. R., Amand A. L., Tomlinson A. J., Benson L. M., Naylor S., Kline B. C., Cockerill F. R., III, Rusnak F. (1997) J. Infect. Dis. 176, 722–727

[40] Pierattelli R., Banci L., Eady N. A., Bodiquel J., Jones J. N., Moody P. C., Raven E. L., Jamart-Grégoire B., Brown K. A. (2004) J. Biol. Chem. 279, 39000–39009